Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

No effective targeted therapies exist for cancers with somatic KRAS mutations. Here we develop a synthetic lethal chemical screen in isogenic KRAS-mutant and wild-type cells to identify clinical drug pairs. Our results show that dual inhibition of polo-like kinase 1 and RhoA/Rho kinase (ROCK) leads...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jieqiong, Hu, Kewen, Guo, Jiawei, Cheng, Feixiong, Lv, Jing, Jiang, Wenhao, Lu, Weiqiang, Liu, Jinsong, Pang, Xiufeng, Liu, Mingyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873974/
https://www.ncbi.nlm.nih.gov/pubmed/27193833
http://dx.doi.org/10.1038/ncomms11363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873974/
https://www.ncbi.nlm.nih.gov/pubmed/27193833
http://dx.doi.org/10.1038/ncomms11363

Ejemplares similares